CoChat

An exploratory clinical study of p38 α kinase inhibition in Alzheimer's disease

Open access
Scheltens, Philip, Prins, Niels, Lammertsma, Adriaan, Yaqub, Maqsood, Gouw, Alida, Wink, Alle Meije, Chu, Hui‐May, van Berckel, Bart N. M., Alam, John · 2018 · Annals of Clinical and Translational Neurology
Cited by 79

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Objective: The aim of this study was to preliminarily evaluate an oral small molecule p38 α kinase inhibitor in patients with early Alzheimer's disease (AD) for the effects on brain amyloid plaque load and episodic memory function, and to establish pharmacokinetic–pharmacodynamics correlations if any effects identified on these parameters. Methods: Sixteen patients with early AD received a highly selective p38 α inhibitor (neflamapimod) for 84 days (12 weeks). To obtain a broad range of plasma drug exposures, subjects randomized to receive either 40 mg (n = 9) or 125 mg (n = 7) twice daily. Dynamic, 11 C‐PiB positron emission scans were performed at baseline and at Day 84 and quantitatively analyzed by reference parametric mapping. Episodic memory assessed as Wechsler Memory Scale (WMS) immediate and delayed recall composites. Result: In the 11 C‐PiB analyses there were no main group level effects, though in the prespecified responder analysis (>7% reduction in 11 C‐PiB signal) there were three responders in the 40 mg, and one in the 125 mg group. There were statistically significant increases from baseline in mean WMS immediate recall score and WMS delayed recall at both day 28 (P = 0.03 and P = 0.001) and day 84 (P = 0.001 and P < 0.001). Individual subject plasma drug concentration profiles were significantly positively correlated with the change in combined WMS immediate and delayed recall (P < 0.0001, r2 = 0.70). Within‐subject effect size was 0.59 for immediate recall and 0.67 for delayed recall. Interpretation: Selective p38 α inhibition in patients with early AD may improve episodic memory and potentially impact β‐amyloid production. These preliminary clinical findings support conduct of a longer duration placebo‐controlled study, particularly to confirm the effects on episodic memory function.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/acn3.549

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 79

Metadata

Authors
Scheltens, P., Prins, N., Lammertsma, A., Yaqub, M., Gouw, A., Wink, A. M., Chu, H., van Berckel, B. N. M., & Alam, J.
Venue
Annals of Clinical and Translational Neurology
Publisher
Wiley
Published
2018-03-06
Volume
5
Issue
4
Pages
464-473
ISSN
2328-9503 (ISSN-L)
OpenAlex
W2793237966
Cited by
79
References
12
FWCI
4.16
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.